Loading
Putting the cancer-seeking receptor on natural killer cells or macrophages instead of T cells, which could be safer and off-the-shelf.
CAR-NK and CAR-macrophage therapies put a chimeric antigen receptor on innate effector cells instead of T cells; NK cells lack graft-versus-host risk, enabling allogeneic, off-the-shelf use with low cytokine release syndrome and neurotoxicity. Cord-blood or iPSC-derived CAR-NK (Nkarta, Fate, Takeda/MD Anderson) show low CRS and allogeneic feasibility, but efficacy durability is the question because persistence is short. CAR-macrophages (Carisma CT-0508, HER2) aim at solid tumour infiltration and phagocytosis, with early and modest results. Manufacturing scale is a further hurdle. The simple version is that these therapies use other immune cells as the cancer-seeking vehicle, promising safety and availability but not yet matching the durable responses of CAR-T.
Innate effector cells engineered with a CAR; NK cells lack GVHD risk enabling allogeneic use.
Nothing in the corpus depends on this yet.
Dependencies are what this technology cannot be delivered without: manufacturing steps, instruments, software, upstream methods. See its full chain on the map.
EB-NK-301 is an experimental CAR-NK cell therapy from Beijing Biotech in phase 2 trials, aimed at TROP2.
One technology page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
One technology page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Query for this technology: (TITLE:"CAR-NK" OR ABSTRACT:"CAR-NK" OR TITLE:"CAR NK" OR ABSTRACT:"CAR NK" OR TITLE:"CAR-macrophage" OR ABSTRACT:"CAR-macrophage" OR TITLE:"CAR macrophage" OR ABSTRACT:"CAR macrophage"). Results are unfiltered search hits about CAR-NK & CAR-macrophage, not a curated reading list.
Shares Engineered immune surveillance: long-lived programmed immune cells that patrol for early cancer, Cell therapy roadmap: CD19 CAR-T → solid tumours → in vivo CAR, CAR-T cell therapy and the tag frontier.
Shares Cell therapy roadmap: CD19 CAR-T → solid tumours → in vivo CAR, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy and the tag frontier.
Shares Manufacturing cost and time for living and radioactive medicines and the tag frontier.
Shares Manufacturing cost and time for living and radioactive medicines and the tag frontier.
Shares Manufacturing cost and time for living and radioactive medicines and the tag frontier.
Shares CAR-T cell therapy and the tag frontier.
Shares CAR-T cell therapy and the tag frontier.
Shares Manufacturing cost and time for living and radioactive medicines and the tag frontier.